Research Article
Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
Table 2
The clinicopathological features of 140 DLBCL patients.
| | Item | GCB group | Non-GCB group | value |
| | 47 | 93 | — | | Age (year) | | | | | | | | 0.283 | | Sex, (%) | | | | | Male | 29 (61.7) | 53 (57.0) | 0.593 | | Female | 18 (38.3) | 40 (43.0) | | Primary localization, (%) | | | | | Extranodal | 30 (63.8) | 64 (68.8) | 0.553 | | Nodal | 17 (36.2) | 29 (31.2) | | C-MYC, (%) | | | | | Positive | 15 (31.9) | 32 (34.4) | 0.768 | | Negative | 32 (68.1) | 61 (65.6) | | BCL-6, (%) | | | | | Positive | 45 (95.7) | 72 (77.4) | 0.006 | | Negative | 2 (4.3) | 21 (22.6) | | MUM-1, (%) | | | | | Positive | 26 (55.3) | 92 (98.9) | ≤0.001 | | Negative | 21 (44.7) | 1 (1.1) | | CD10, (%) | | | | | Positive | 31 (66.0) | 0 (0) | ≤0.001 | | Negative | 16 (34.0) | 93 (100) | | LDH, (%) | | | | | Positive | 12 (25.5) | 26 (28.0) | 0.761 | | Negative | 35 (74.5) | 67 (72.0) | | SCr, (%) | | | | | Positive | 1 (2.1) | 5 (5.4) | 0.664 | | Negative | 46 (97.9) | 88 (94.6) | | Monocyte count (109/L), (%) | | | | | Decreased or increased | 12 (25.5) | 32 (34.4) | 0.285 | | Normal | 35 (74.5) | 61 (65.6) | | RBC (109/L), (%) | | | | | Decreased or increased | 27 (57.4) | 58 (62.4) | 0.574 | | Normal | 20 (42.6) | 35 (37.6) | | Hemoglobin (g/L), (%) | | | | | Decreased or increased | 13 (27.7) | 31 (33.3) | 0.495 | | Normal | 34 (72.3) | 62 (66.7) | | Platelet count (109/L), (%) | | | | | Decreased or increased | 13 (27.7) | 20 (21.5) | 0.418 | | Normal | 34 (72.3) | 73 (78.5) | | WBC (109/l), (%) | | | | | Decreased or increased | 10 (21.3) | 20 (21.5) | 0.975 | | Normal | 37 (78.7) | 73 (78.5) | | LDH, (%) | | | | | Positive | 28 (59.6) | 38 (40.9) | 0.036 | | Negative | 19 (40.4) | 55 (59.1) | | Ki67, (%) | | | | | ≥70% | 34 (72.3) | 63 (67.7) | 0.578 | | <70% | 13 (27.7) | 30 (32.3) | | ECOG PS, (%) | | | | | ≥2 | 18 (38.3) | 50 (53.8) | 0.084 | | <2 | 29 (61.7) | 43 (46.2) | | Ann Arbor stage, (%) | | | | | I-II (early stage) | 11 (23.4) | 17 (18.3) | 0.474 | | III-IV (late stage) | 36 (76.6) | 76 (81.7) | | B symptoms, (%) | | | | | Positive | 7 (14.9) | 26 (28.0) | 0.085 | | Negative | 40 (85.1) | 67 (72.0) | | aaIPI, (%) | | | | | >2 | 6 (12.8) | 25 (26.9) | 0.057 | | ≤2 | 41 (87.2) | 68 (73.1) | | Treatment options, (%) | | | | | Comprehensive treatment | 20 (42.6) | 39 (41.9) | 0.944 | | Operation or chemotherapy | 27 (57.4) | 54 (58.1) |
|
|
represents statistical differences. DLBCL: diffuse large B cell lymphoma; LDH: lactate dehydrogenase; SCr: serum creatinine; WBC: white blood cell count; RBC: red blood cell count; GCB subtype: germinal center B cell-like subtype; Non-GCB subtype: nongerminal center B cell-like subtype; ECOG PS: Eastern Cooperative Oncology Group performance status. |
